Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Adenocarcinoma
Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.
Adenocarcinoma
Isocitrate dehydrogenase-1 is mutated in inflammatory bowel disease-associated intestinal adenocarcinoma with low-grade tubuloglandular histology but not in sporadic intestinal adenocarcinoma.
Adenocarcinoma
Wild-Type Isocitrate Dehydrogenase 1 Over-Expression is Related to Cancer Stem Cells Survival in Lung Adenocarcinoma.
Adenocarcinoma of Lung
Wild-Type Isocitrate Dehydrogenase 1 Over-Expression is Related to Cancer Stem Cells Survival in Lung Adenocarcinoma.
Adenoma
Spironolactone bodies in aldosteronomas and in the attached adrenals. Enzyme histochemical study of 19 cases of primary aldosteronism and a case of aldosteronism due to bilateral diffuse hyperplasia of the zona glomerulosa.
alpha-Thalassemia
Molecular profile of tumors with oligodendroglial morphology: Clinical relevance.
Arteriovenous Malformations
Arteriovenous malformation within an isocitrate dehydrogenase 1 mutated anaplastic oligodendroglioma.
Astrocytoma
A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53.
Astrocytoma
A Simple Panel of IDH1 and P53 in Differential Diagnosis Between Low-Grade Astrocytoma and Reactive Gliosis.
Astrocytoma
Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
Astrocytoma
Confirmation of R132H mutation of isocitrate dehydrogenase 1 as an independent prognostic factor in anaplastic astrocytoma.
Astrocytoma
Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing.
Astrocytoma
Diagnostic and prognostic markers in gliomas.
Astrocytoma
Evaluation of the melting temperature of TaqMan probes as a genotyping method for IDH1, IDH2, and H3F3A in pediatric astrocytomas.
Astrocytoma
Expression of pERK and pAKT in human astrocytomas: correlation with IDH1-R132H presence, vascular endothelial growth factor, microvascular characteristics and clinical outcome.
Astrocytoma
FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas.
Astrocytoma
Generation and Performance of R132H Mutant IDH1 Rabbit Monoclonal Antibody.
Astrocytoma
Genetic alterations and signaling pathways in the evolution of gliomas.
Astrocytoma
Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma.
Astrocytoma
IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy.
Astrocytoma
IDH1 R132H mutation in a pilocytic astrocytoma: a case report.
Astrocytoma
IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients.
Astrocytoma
Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation.
Astrocytoma
Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
Astrocytoma
Metabolic modulation of epigenetics in gliomas.
Astrocytoma
Molecular pathogenesis of IDH mutations in gliomas.
Astrocytoma
Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
Astrocytoma
No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas.
Astrocytoma
Noninvasively detecting Isocitrate dehydrogenase 1 gene status in astrocytoma by dynamic susceptibility contrast MRI.
Astrocytoma
Pathological classification of brain tumors.
Astrocytoma
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Astrocytoma
PCR- and Restriction Endonuclease-Based Detection of IDH1 Mutations.
Astrocytoma
Spinal Cord Astrocytoma with Isocitrate Dehydrogenase 1 Gene Mutation.
Astrocytoma
Survival of diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
Astrocytoma
The Evaluation of AREG, MMP-2, CHI3L1, GFAP, and OPN Serum Combined Value in Astrocytic Glioma Patients' Diagnosis and Prognosis.
Astrocytoma
The Role of CASC2 and miR-21 Interplay in Glioma Malignancy and Patient Outcome.
Astrocytoma
The role of FilGAP, a Rac-specific Rho-GTPase-activating protein, in tumor progression and behavior of astrocytomas.
Astrocytoma
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Biliary Tract Neoplasms
Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come.
Brain Neoplasms
5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations.
Brain Neoplasms
An R132H Mutation in Isocitrate Dehydrogenase 1 Enhances p21 Expression and Inhibits Phosphorylation of Retinoblastoma Protein in Glioma Cells.
Brain Neoplasms
Application of denaturing capillary electrophoresis for the detection of prognostic mutations in isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 genes in brain tumors.
Brain Neoplasms
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Brain Neoplasms
CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells.
Brain Neoplasms
Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism.
Brain Neoplasms
Concurrent IDH1 and SMARCB1 Mutations in Pediatric Medulloblastoma: A Case Report.
Brain Neoplasms
Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.
Brain Neoplasms
Heterozygous IDH1R132H/WT created by "single base editing" inhibits human astroglial cell growth by downregulating YAP.
Brain Neoplasms
High-throughput immunohistochemical profiling of primary brain tumors and non-neoplastic systemic organs with a specific antibody against the mutant isocitrate dehydrogenase 1 R132H protein.
Brain Neoplasms
Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma.
Brain Neoplasms
IDH1R132H Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells.
Brain Neoplasms
Intracerebral Distribution of the Oncometabolite d-2-Hydroxyglutarate in Mice Bearing Mutant Isocitrate Dehydrogenase Brain Tumors: Implications for Tumorigenesis.
Brain Neoplasms
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma.
Brain Neoplasms
Magnetic resonance spectroscopy for the study of cns malignancies.
Brain Neoplasms
Methylation associated genes contribute to the favorable prognosis of gliomas with isocitrate dehydrogenase 1 mutation.
Brain Neoplasms
Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.
Brain Neoplasms
Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.
Brain Neoplasms
On the Utility of Short Echo Time (TE) Single Voxel 1H-MRS in Non-Invasive Detection of 2-Hydroxyglutarate (2HG); Challenges and Potential Improvement Illustrated with Animal Models Using MRUI and LCModel.
Brain Neoplasms
Prognostic factors and clinical outcomes in adult primary gliosarcoma patients: a Surveillance, Epidemiology, and End Results (SEER) analysis from 2004 to 2015.
Brain Neoplasms
Prognostic value of IDH1 mutations identified with PCR-RFLP assay in acute myeloid leukemia patients.
Brain Neoplasms
Prognostic value of IDH1 mutations identified with PCR-RFLP assay in glioblastoma patients.
Brain Neoplasms
The effect of race on the prognosis of the glioblastoma patient: a brief review.
Brain Neoplasms
Tissue mechanics promote IDH1-dependent HIF1?-tenascin C feedback to regulate glioblastoma aggression.
Breast Neoplasms
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
Breast Neoplasms
Nuclear receptor 4A1 as a drug target for breast cancer chemotherapy.
Breast Neoplasms
Relationship of glycolytic enzyme activities and response of breast cancer patients to chemotherapy: A preliminary report.
Carcinogenesis
Altered Expression of Oxidative Metabolism Related Genes in Cholangiocarcinomas.
Carcinogenesis
Cancer-associated IDH mutations induce Glut1 expression and glucose metabolic disorders through a PI3K/Akt/mTORC1-Hif1? axis.
Carcinogenesis
Detection of Metabolic Changes Induced via Drug Treatments in Live Cancer Cells and Tissue Using Raman Imaging Microscopy.
Carcinogenesis
Digital Droplet PCR is a Specific and Sensitive Tool for Detecting IDH2 Mutations in Acute Myeloid LeuKemia Patients.
Carcinogenesis
Discovery of ?-mangostin as a novel competitive inhibitor against mutant isocitrate dehydrogenase-1.
Carcinogenesis
IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.
Carcinogenesis
Intracerebral Distribution of the Oncometabolite d-2-Hydroxyglutarate in Mice Bearing Mutant Isocitrate Dehydrogenase Brain Tumors: Implications for Tumorigenesis.
Carcinogenesis
Isocitrate dehydrogenase 1 is downregulated during early skin tumorigenesis which can be inhibited by overexpression of manganese superoxide dismutase.
Carcinogenesis
Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.
Carcinogenesis
Molecular mechanisms of "off-on switch" of activities of human IDH1 by tumor-associated mutation R132H.
Carcinogenesis
The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.
Carcinogenesis
The emerging role of fumarate as an oncometabolite.
Carcinogenesis
Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid.
Carcinogenesis
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.
Carcinoma
Immunohistochemical Demonstration of Isocitrate Dehydrogenase 1 (IDH1) Mutation in a Small Subset of Prostatic Carcinomas.
Carcinoma
Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma.
Carcinoma
Prognostic and diagnostic potential of isocitrate dehydrogenase 1 in esophageal squamous cell carcinoma.
Carcinoma
Proteome of Metastatic Canine Mammary Carcinomas: Similarities to and Differences from Human Breast Cancer ().
Carcinoma
Relationship of glycolytic enzyme activities and response of breast cancer patients to chemotherapy: A preliminary report.
Carcinoma
Squamous cell carcinoma arising in dedifferentiated chondrosarcoma proved by isocitrate dehydrogenase mutation analysis.
Carcinoma
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Carcinoma, Ehrlich Tumor
Changes in enzyme pattern of Ehrlich ascites tumor cells following serial cultivation in media with increased (hypertonic) NaCl content.
Carcinoma, Hepatocellular
Calcium sensitive isocitrate and 2-oxoglutarate dehydrogenase activities in rat liver and AS-30D hepatoma mitochondria.
Carcinoma, Non-Small-Cell Lung
Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis.
Carcinoma, Non-Small-Cell Lung
Isocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancer.
Carcinoma, Renal Cell
Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma.
Carcinoma, Squamous Cell
Squamous cell carcinoma arising in dedifferentiated chondrosarcoma proved by isocitrate dehydrogenase mutation analysis.
Carcinoma, Squamous Cell
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Cardiotoxicity
A possible mechanism of adriamycin cardiotoxicity. Inhibition of NADP-linked isocitrate dehydrogenase.
Central Nervous System Neoplasms
Correlation between IDH, ATRX, and TERT promoter mutations in glioma.
Chemical and Drug Induced Liver Injury
[The intensity of free radical oxidation and catalytic properties of the rat liver NADP-isocitrate dehydrogenase in the norm and in toxic hepatitis]
Chemical and Drug Induced Liver Injury
[Thioctic acid action on glutathione-dependent antioxidant system functioning at toxic hepatitis of rats]
Cholangiocarcinoma
A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors.
Cholangiocarcinoma
Advances in Brain Cancer: Creating Monoallelic Single Point Mutation in IDH1 by Single Base Editing.
Cholangiocarcinoma
Association of TP53 Alteration with Tissue Specificity and Patient Outcome of IDH1-Mutant Glioma.
Cholangiocarcinoma
Biliary tract cancer.
Cholangiocarcinoma
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options.
Cholangiocarcinoma
Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review.
Cholangiocarcinoma
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
Cholangiocarcinoma
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma.
Cholangiocarcinoma
Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1.
Cholangiocarcinoma
Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma.
Cholangiocarcinoma
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Cholangiocarcinoma
Mutant IDH inhibits HNF-4? to block hepatocyte differentiation and promote biliary cancer.
Cholangiocarcinoma
Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism.
Cholangiocarcinoma
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
Cholangiocarcinoma
Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma.
Cholangiocarcinoma
Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.
Cholangiocarcinoma
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.
Cholangiocarcinoma
The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.
Chondroma
Chondroma arising from the spinal dura mater at the thoracic level: A case report with molecular analysis.
Chondroma
Enchondromatosis and Growth Plate Development.
Chondroma
Maffucci Syndrome with Clival Enchondroma in Nasopharynx: A Case Report.
Chondroma
Recurrent 12q13-15 chromosomal aberrations, high frequency of isocitrate dehydrogenase 1 mutations, and absence of high mobility group AT-hook 2 expression in periosteal chondromas.
Chondromatosis
IDH1 mutated acute myeloid leukemia in a child with metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria.
Chondrosarcoma
A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors.
Chondrosarcoma
Advances in Brain Cancer: Creating Monoallelic Single Point Mutation in IDH1 by Single Base Editing.
Chondrosarcoma
An orthotopic mouse model for chondrosarcoma of bone provides an in vivo tool for drug testing.
Chondrosarcoma
Association of Clinicopathological Features With Outcome in Chondrosarcomas of the Head and Neck.
Chondrosarcoma
Association of TP53 Alteration with Tissue Specificity and Patient Outcome of IDH1-Mutant Glioma.
Chondrosarcoma
Chondroma arising from the spinal dura mater at the thoracic level: A case report with molecular analysis.
Chondrosarcoma
Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone.
Chondrosarcoma
Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma.
Chondrosarcoma
IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Chondrosarcoma
IDH mutation status in a series of 88 head and neck chondrosarcomas: different profile between tumors of the Skull Base and tumors involving the facial skeleton and the Layngotracheal tract.
Chondrosarcoma
Induction of sarcomas by mutant IDH2.
Chondrosarcoma
Inhibitor potency varies widely among tumor-relevant human isocitrate dehydrogenase 1 mutants.
Chondrosarcoma
Isocitrate dehydrogenase 1 mutations (IDH1) and p16/CDKN2A copy number change in conventional chondrosarcomas.
Chondrosarcoma
Metabolic consequences of oncogenic IDH mutations.
Chondrosarcoma
Mutant IDH and non-mutant chondrosarcomas display distinct cellular metabolomes.
Chondrosarcoma
Mutant IDH1 is required for IDH1 mutated tumor cell growth.
Chondrosarcoma
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.
Chondrosarcoma
NAD Synthesis Pathway Interference is a Viable Therapeutic Strategy for Chondrosarcoma.
Chondrosarcoma
Novel canine isocitrate dehydrogenase 1 mutation Y208C attenuates dimerization ability.
Chondrosarcoma
Novel Multiplex Bead-Based Assay for Detection of IDH1 and IDH2 Mutations in Myeloid Malignancies.
Chondrosarcoma
Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.
Chondrosarcoma
Squamous cell carcinoma arising in dedifferentiated chondrosarcoma proved by isocitrate dehydrogenase mutation analysis.
Chondrosarcoma
The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.
Chondrosarcoma
Water Networks and Correlated Motions in Mutant Isocitrate Dehydrogenase 1 (IDH1) Are Critical for Allosteric Inhibitor Binding and Activity.
Colorectal Neoplasms
Isocitrate dehydrogenase 1 R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype.
Colorectal Neoplasms
Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come.
Coma
[Energy metabolic changes and nerve cell damage in rats exposed to multiple administration of large-dose insulin].
Dehydration
Activity of isocitrate dehydrogenase from three filamentous fungi in relation to osmotic and solute effects.
Dehydration
Sucrose phosphate synthase activity and the co-ordination of carbon partitioning during sucrose and amino acid accumulation in desiccation-tolerant leaf material of the C4 resurrection plant Sporobolus stapfianus during dehydration.
Dermatitis, Phototoxic
Cellular defense against UVB-induced phototoxicity by cytosolic NADP(+)-dependent isocitrate dehydrogenase.
Enchondromatosis
Constitutional abnormalities of IDH1 combined with secondary mutations predispose a patient with Maffucci syndrome to acute lymphoblastic leukemia.
Enchondromatosis
Ovarian cellular fibroma harbouring an isocitrate dehydrogenase 1 (1DH1) mutation in a patient with Ollier disease: evidence for a causal relationship.
Enchondromatosis
The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo.
Ependymoma
Lack of IDH1 mutation in astroblastomas suggests putative origin from ependymoglial cells?
Epilepsy
Correlation Between Tumor Molecular Markers and Perioperative Epilepsy in Patients With Glioma: A Systematic Review and Meta-Analysis.
Esophageal Squamous Cell Carcinoma
Prognostic and diagnostic potential of isocitrate dehydrogenase 1 in esophageal squamous cell carcinoma.
Fibroma
Ovarian cellular fibroma harbouring an isocitrate dehydrogenase 1 (1DH1) mutation in a patient with Ollier disease: evidence for a causal relationship.
Fibrosarcoma
Detection of Metabolic Changes Induced via Drug Treatments in Live Cancer Cells and Tissue Using Raman Imaging Microscopy.
Ganglioglioma
Isocitrate Dehydrogenase 1 Analysis Differentiates Gangliogliomas from Infiltrative Gliomas.
Ganglioneuroma
A case of oligodendroglioma with prominent neuronal differentiation.
Glioblastoma
A high-throughput SAMDI-mass spectrometry assay for isocitrate dehydrogenase 1.
Glioblastoma
A Mistaken Diagnosis of Secondary Glioblastoma as Parasitosis.
Glioblastoma
A novel isocitrate dehydrogenase 1 G131D mutation in glioblastoma.
Glioblastoma
A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma.
Glioblastoma
A radiomics-clinical nomogram for preoperative prediction of IDH1 mutation in primary glioblastoma multiforme.
Glioblastoma
Adult cerebellar glioblastoma cases have different characteristics from supratentorial glioblastoma.
Glioblastoma
An IDH1-mutated primary gliosarcoma: case report.
Glioblastoma
Analysis of NADP+-dependent isocitrate dehydrogenase-1/2 gene mutations in pediatric brain tumors: report of a secondary anaplastic astrocytoma carrying the IDH1 mutation.
Glioblastoma
Angiogenin Upregulation Independently Predicts Unfavorable Overall Survival in Proneural Subtype of Glioblastoma.
Glioblastoma
Anion-exchange chromatography mass spectrometry provides extensive coverage of primary metabolic pathways revealing altered metabolism in IDH1 mutant cells.
Glioblastoma
Assessment of the Association between Isocitrate Dehydrogenase 1 Mutation and Mortality Risk of Glioblastoma Patients.
Glioblastoma
Biochemical, Cellular and Biophysical Characterization of a Potent Inhibitor of Mutant Isocitrate Dehydrogenase IDH1.
Glioblastoma
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
Glioblastoma
CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells.
Glioblastoma
Clinical Neuropathology Practice News 2-2013: immunohistochemistry pins IDH in glioma - molecular testing procedures under scrutiny.
Glioblastoma
Clinical prognostic value of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in glioblastoma.
Glioblastoma
Clinicopathological Analysis of HIF-1alpha and TERT on Survival Outcome in Glioblastoma Patients: A Prospective, Single Institution Study.
Glioblastoma
Comparative study of IDH1 mutations in gliomas by high resolution melting analysis, immunohistochemistry and direct DNA sequencing.
Glioblastoma
Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma.
Glioblastoma
Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.
Glioblastoma
Correlation of immunohistochemical expression of HIF-1alpha and IDH1 with clinicopathological and therapeutic data of moroccan glioblastoma and survival analysis.
Glioblastoma
Defective p53 antiangiogenic signaling in glioblastoma.
Glioblastoma
Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy.
Glioblastoma
Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing.
Glioblastoma
Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants.
Glioblastoma
Differential and Prognostic Significance of HOXB7 in Gliomas.
Glioblastoma
Distinct demographic profile and molecular markers of primary CNS tumor in 1873 adolescent and young adult patient population.
Glioblastoma
EGFR, p53, IDH-1 and MDM2 immunohistochemical analysis in glioblastoma: therapeutic and prognostic correlation.
Glioblastoma
Energy Metabolism in IDH1 Wild-Type and IDH1-Mutated Glioblastoma Stem Cells: A Novel Target for Therapy?
Glioblastoma
Epigenetic suppression of EGFR signaling in G-CIMP+ glioblastomas.
Glioblastoma
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.
Glioblastoma
Extracranial Metastasis of IDH-1 Wild Type Glioblastomas.
Glioblastoma
Friend or foe-IDH1 mutations in glioma 10 years on.
Glioblastoma
Generation and Performance of R132H Mutant IDH1 Rabbit Monoclonal Antibody.
Glioblastoma
Genetic alterations and signaling pathways in the evolution of gliomas.
Glioblastoma
Genetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 Mutation.
Glioblastoma
Genome-wide transcriptional analyses of Chinese patients reveal cell migration is attenuated in IDH1-mutant glioblastomas.
Glioblastoma
Glioblastoma in a female neurofibromatosis 1 patient without IDH1, BRAF V600E, and TERT promoter mutations: A case report.
Glioblastoma
Glioblastoma in neurofibromatosis 1 patients without IDH1, BRAF V600E, and TERT promoter mutations.
Glioblastoma
Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma.
Glioblastoma
Gliosis versus glioma?: don't grade until you know.
Glioblastoma
Glutamate is a non-invasive metabolic biomarker of IDH1 mutant glioma response to temozolomide treatment.
Glioblastoma
Gold Nanoparticle Size and Shape Effects on Cellular Uptake and Intracellular Distribution of siRNA Nanoconstructs.
Glioblastoma
High-throughput immunohistochemical profiling of primary brain tumors and non-neoplastic systemic organs with a specific antibody against the mutant isocitrate dehydrogenase 1 R132H protein.
Glioblastoma
Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma.
Glioblastoma
Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma.
Glioblastoma
Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer.
Glioblastoma
Identification of a long noncoding RNA signature to predict outcomes of glioblastoma.
Glioblastoma
Identification of Retinol Binding Protein 1 Promoter Hypermethylation in Isocitrate Dehydrogenase 1 and 2 Mutant Gliomas.
Glioblastoma
IDH mutations in glioma and acute myeloid leukemia.
Glioblastoma
IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee.
Glioblastoma
IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice.
Glioblastoma
IDH1 and IDH2 mutations in gliomas.
Glioblastoma
IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy.
Glioblastoma
IDH1 mutation is associated with improved overall survival in patients with glioblastoma: a meta-analysis.
Glioblastoma
IDH1 mutation may not be prognostically favorable in glioblastoma when controlled for tumor location: A case-control study.
Glioblastoma
IDH1 mutation of gliomas with long-term survival analysis.
Glioblastoma
IDH1 mutation prediction using MR-based radiomics in glioblastoma: comparison between manual and fully automated deep learning-based approach of tumor segmentation.
Glioblastoma
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.
Glioblastoma
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.
Glioblastoma
IDH1R132H Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells.
Glioblastoma
IDH1R¹³²H decreases the proliferation of U87 glioma cells through upregulation of microRNA-128a.
Glioblastoma
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.
Glioblastoma
In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma.
Glioblastoma
In vivo characterization of physiological and metabolic changes related to isocitrate dehydrogenase 1 mutation expcression by multiparametric MRI and MRS in a rat model with orthotopically grafted human-derived glioblastoma cell lines.
Glioblastoma
Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry.
Glioblastoma
Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer.
Glioblastoma
Inhibitor potency varies widely among tumor-relevant human isocitrate dehydrogenase 1 mutants.
Glioblastoma
Integrative analysis of DNA methylation suggests down-regulation of oncogenic pathways and reduced somatic mutation rates in survival outliers of glioblastoma.
Glioblastoma
Intramedullary spinal glioblastoma metastasis from anaplastic astrocytoma of cerebellum: A case report and review of the literature.
Glioblastoma
Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status.
Glioblastoma
Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type.
Glioblastoma
Isocitrate Dehydrogenase 1 Analysis Differentiates Gangliogliomas from Infiltrative Gliomas.
Glioblastoma
Isocitrate Dehydrogenase 1 Expression in Canine Gliomas.
Glioblastoma
Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
Glioblastoma
Isocitrate dehydrogenase 1 gene variants analysis of glioma patients from Pakistan.
Glioblastoma
Isocitrate dehydrogenase 1 mutant glioblastomas demonstrate a decreased rate of pseudoprogression: a multi-institutional experience.
Glioblastoma
Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
Glioblastoma
Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review.
Glioblastoma
Isocitrate dehydrogenase 1R132H mutation in microglia/macrophages in gliomas: Indication of a significant role of microglia/macrophages in glial tumorigenesis.
Glioblastoma
Isocitrate dehydrogenase mutations in gliomas.
Glioblastoma
Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia.
Glioblastoma
Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?
Glioblastoma
Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.
Glioblastoma
Location-Dependent Patient Outcome and Recurrence Patterns in IDH1-Wildtype Glioblastoma.
Glioblastoma
Malignant Transformation of a Rosette-Forming Glioneuronal Tumor with IDH1 Mutation: A Case Report and Literature Review.
Glioblastoma
Metabolic modulation of epigenetics in gliomas.
Glioblastoma
Molecular pathogenesis of IDH mutations in gliomas.
Glioblastoma
MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma.
Glioblastoma
Multiregional radiomics profiling from multiparametric MRI: Identifying an imaging predictor of IDH1 mutation status in glioblastoma.
Glioblastoma
Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Glioblastoma
Mutant IDH1 Promotes Glioma Formation In Vivo.
Glioblastoma
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
Glioblastoma
NADP(+)-dependent IDH1(R132) mutation and its relevance for glioma patient survival.
Glioblastoma
No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas.
Glioblastoma
Non-invasive in vivo assessment of IDH1 mutational status in glioma.
Glioblastoma
Oncogenic MicroRNA-20a is downregulated by the HIF-1?/c-MYC pathway in IDH1 R132H-mutant glioma.
Glioblastoma
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors.
Glioblastoma
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Glioblastoma
Phosphorous Magnetic Resonance Spectroscopy and Molecular Markers in IDH1 Wild Type Glioblastoma.
Glioblastoma
PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival.
Glioblastoma
Prediction of IDH1 Mutation Status in the Glioblastoma Using the Machine Learning Technique Based on the Quantitative Radiomic Data.
Glioblastoma
Presentation of treatment effect in glioblastoma after dose-escalation radiation therapy.
Glioblastoma
Prognostic factors and clinical outcomes in adult primary gliosarcoma patients: a Surveillance, Epidemiology, and End Results (SEER) analysis from 2004 to 2015.
Glioblastoma
Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma.
Glioblastoma
Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
Glioblastoma
Prognostic value of IDH1 mutations identified with PCR-RFLP assay in glioblastoma patients.
Glioblastoma
Prognostic Value of MGMT Promoter Methylation and TP53 Mutation in Glioblastomas Depends on IDH1 Mutation.
Glioblastoma
Progressive adult primary glioblastoma in the medulla oblongata with an unmethylated MGMT promoter and without an IDH mutation.
Glioblastoma
PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma.
Glioblastoma
Radiomic MRI signature reveals three distinct subtypes of glioblastoma with different clinical and molecular characteristics, offering prognostic value beyond IDH1.
Glioblastoma
Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis.
Glioblastoma
Recurrent pseudoprogression in isocitrate dehydrogenase 1 mutant glioblastoma.
Glioblastoma
Reprogramming the immunosuppressive microenvironment of IDH1 wild-type glioblastoma by blocking Wnt signaling between microglia and cancer cells.
Glioblastoma
Sparse Representation-Based Radiomics for the Diagnosis of Brain Tumors.
Glioblastoma
Spinal Drop Metastasis of Glioblastoma-Two Case Reports, Clinicopathologic Features, Current Modalities of Evaluation, and Treatment with a Review of the Literature.
Glioblastoma
Structural, Kinetic and Chemical Mechanism of Isocitrate Dehydrogenase-1 from Mycobacterium tuberculosis.
Glioblastoma
Survival of diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
Glioblastoma
The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.
Glioblastoma
The effect of race on the prognosis of the glioblastoma patient: a brief review.
Glioblastoma
The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.
Glioblastoma
The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents.
Glioblastoma
The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma.
Glioblastoma
The role of IDH1 mutated tumour cells in secondary glioblastomas: an evolutionary game theoretical view.
Glioblastoma
The role of neuropathology in the management of newly diagnosed glioblastoma: a systematic review and evidence-based clinical practice guideline.
Glioblastoma
Transdural Propagation of Glioblastoma Through Foramen Rotundum.
Glioblastoma
Virtual mutagenesis of isocitrate dehydrogenase 1 involved in glioblastoma multiforme.
Glioblastoma
Water Networks and Correlated Motions in Mutant Isocitrate Dehydrogenase 1 (IDH1) Are Critical for Allosteric Inhibitor Binding and Activity.
Glioblastoma
What's New in Grade II and Grade III Gliomas?
Glioblastoma
[Clinical, immunohistochemical, and molecular genetic prognostic factors in adult patients with glioblastoma].
Glioma
1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth.
Glioma
2-hydroxyglutarate-mediated autophagy of the endoplasmic reticulum leads to an unusual downregulation of phospholipid biosynthesis in mutant IDH1 gliomas.
Glioma
5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.
Glioma
5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma.
Glioma
A functional variant on 20q13.33 related to glioma risk alters enhancer activity and modulates expression of multiple genes.
Glioma
A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas.
Glioma
A map of the altered glioma metabolism.
Glioma
A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres.
Glioma
A mRMRMSRC feature selection method for radiomics approach.
Glioma
A novel COLD-PCR/FMCA assay enhances the detection of low-abundance IDH1 mutations in gliomas.
Glioma
A novel high-sensitivity assay to detect a small fraction of mutant IDH1 using droplet digital PCR.
Glioma
A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation.
Glioma
A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors.
Glioma
A population-based study of high-grade gliomas and mutated isocitrate dehydrogenase 1.
Glioma
A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1).
Glioma
A retrospective analysis of the risk factors affecting recurrence time in patients with recurrent glioblastoma.
Glioma
A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53.
Glioma
A simple algorithmic approach using histology and immunohistochemistry for the current classification of adult diffuse glioma in a resource-limited set-up.
Glioma
Adjunctive perampanel for glioma-associated epilepsy.
Glioma
Advances in Brain Cancer: Creating Monoallelic Single Point Mutation in IDH1 by Single Base Editing.
Glioma
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.
Glioma
Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
Glioma
Amide Proton Transfer Imaging in Predicting Isocitrate Dehydrogenase 1 Mutation Status of Grade II/III Gliomas Based on Support Vector Machine.
Glioma
An IDH1 mutation inhibits growth of glioma cells via GSH depletion and ROS generation.
Glioma
An IDH1-mutated primary gliosarcoma: case report.
Glioma
An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas.
Glioma
An R132H Mutation in Isocitrate Dehydrogenase 1 Enhances p21 Expression and Inhibits Phosphorylation of Retinoblastoma Protein in Glioma Cells.
Glioma
Analysis of IDH1 and IDH2 mutations in Japanese glioma patients.
Glioma
Analysis of Isocitrate Dehydrogenase 1 Mutation in 97 Patients with Glioma.
Glioma
Analysis of NADP+-dependent isocitrate dehydrogenase-1/2 gene mutations in pediatric brain tumors: report of a secondary anaplastic astrocytoma carrying the IDH1 mutation.
Glioma
Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas.
Glioma
Anatomical location differences between mutated and wild-type isocitrate dehydrogenase 1 in low-grade gliomas.
Glioma
Application of denaturing capillary electrophoresis for the detection of prognostic mutations in isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 genes in brain tumors.
Glioma
Arterial Spin Labeling for Glioma Grade Discrimination: Correlations with IDH1 Genotype and 1p/19q Status.
Glioma
Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.
Glioma
Association Between Histopathology and Magnetic Resonance Imaging Texture in Grading Gliomas Based on Intraoperative Magnetic Resonance Navigated Stereotactic Biopsy.
Glioma
Association of TP53 Alteration with Tissue Specificity and Patient Outcome of IDH1-Mutant Glioma.
Glioma
Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification.
Glioma
Biphasic IDH1 phenotype in a diffusely infiltrating glioma: implications for pathogenesis, treatment and prognosis.
Glioma
Brain T1? mapping for grading and IDH1 gene mutation detection of gliomas: a preliminary study.
Glioma
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
Glioma
Characterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence.
Glioma
Chemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma.
Glioma
CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Glioma
Clinical Neuropathology Practice News 2-2013: immunohistochemistry pins IDH in glioma - molecular testing procedures under scrutiny.
Glioma
Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.
Glioma
Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors.
Glioma
COLD PCR HRM: A highly sensitive detection method for IDH1 mutations.
Glioma
Combination of the Distance From Tumor Edge to Subventricular Zone and IDH Mutation Predicts Prognosis of Patients With Glioma.
Glioma
Combined "Infiltrating Astrocytoma/Pleomorphic Xanthoastrocytoma" Harboring IDH1 R132H and BRAF V600E Mutations.
Glioma
Combined texture analysis of diffusion-weighted imaging with conventional MRI for non-invasive assessment of IDH1 mutation in anaplastic gliomas.
Glioma
Comparative analysis of the diffusion kurtosis imaging and diffusion tensor imaging in grading gliomas, predicting tumour cell proliferation and IDH-1 gene mutation status.
Glioma
Comparative study of IDH1 mutations in gliomas by high resolution melting analysis, immunohistochemistry and direct DNA sequencing.
Glioma
Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.
Glioma
Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas.
Glioma
Comprehensive Analysis of Short-, Medium-, and Long-Chain Acyl-Coenzyme A by Online Two-Dimensional Liquid Chromatography/Mass Spectrometry.
Glioma
Comprehensive Metabolomic Analysis of IDH1R132H Clinical Glioma Samples Reveals Suppression of ?-oxidation Due to Carnitine Deficiency.
Glioma
Computational Analysis of IDH1, IDH2, and TP53 Mutations in Low-Grade Gliomas Including Oligodendrogliomas and Astrocytomas.
Glioma
Concurrent IDH1 and SMARCB1 Mutations in Pediatric Medulloblastoma: A Case Report.
Glioma
Contrahemispheric Cortex Predicts Survival and Molecular Markers in Patients With Unilateral High-Grade Gliomas.
Glioma
Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma.
Glioma
Current and future tools for determination and monitoring of isocitrate dehydrogenase status in gliomas.
Glioma
Cystathionine-?-lyase drives antioxidant defense in cysteine-restricted IDH1-mutant astrocytomas.
Glioma
D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function.
Glioma
D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma.
Glioma
Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation.
Glioma
Deep Learning based Radiomics (DLR) and its usage in noninvasive IDH1 prediction for low grade glioma.
Glioma
Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy.
Glioma
Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation.
Glioma
Detection of IDH1 and IDH2 Mutations by Fluorescence Melting Curve Analysis as a Diagnostic Tool for Brain Biopsies.
Glioma
Detection of Metabolic Changes Induced via Drug Treatments in Live Cancer Cells and Tissue Using Raman Imaging Microscopy.
Glioma
Determining optimal treatment strategy for diffuse glioma: the emerging role of IDH mutations.
Glioma
Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade Glioma.
Glioma
Development of a Rapid and Sensitive IDH1/2 Mutation Detection Method for Glial Tumors and a Comparative Mutation Analysis of 236 Glial Tumor Samples.
Glioma
Diagnostic and prognostic markers in gliomas.
Glioma
Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants.
Glioma
Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
Glioma
Differential activity of NADPH-producing dehydrogenases renders rodents unsuitable models to study IDH1R132 mutation effects in human glioblastoma.
Glioma
Differential and Prognostic Significance of HOXB7 in Gliomas.
Glioma
Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.
Glioma
Diffusion kurtosis imaging combined with molecular markers as a comprehensive approach to predict overall survival in patients with gliomas.
Glioma
Discovery and Optimization of 2H-1?2-Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer.
Glioma
Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.
Glioma
Dual-Knockout of Mutant Isocitrate Dehydrogenase 1 and 2 Subtypes Towards Glioma Therapy: Structural Mechanistic Insights on the Role of Vorasidenib.
Glioma
Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.
Glioma
Enzymes related to energy metabolism in human gliomas.
Glioma
Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
Glioma
Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation.
Glioma
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.
Glioma
Exploring the regulatory role of isocitrate dehydrogenase mutant protein on glioma stem cell proliferation.
Glioma
Expression of mutated isocitrate dehydrogenase-1 in gliomas is associated with p53 and EGFR expression.
Glioma
Extent of BOLD Vascular Dysregulation Is Greater in Diffuse Gliomas without Isocitrate Dehydrogenase 1 R132H Mutation.
Glioma
Extracellular glutamate and IDH1R132H inhibitor promote glioma growth by boosting redox potential.
Glioma
Friend or foe-IDH1 mutations in glioma 10 years on.
Glioma
From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma.
Glioma
Functional requirement of a wild-type allele for mutant IDH1 to suppress anchorage-independent growth through redox homeostasis.
Glioma
Gene markers in brain tumors: what the epileptologist should know.
Glioma
Generation of induced neural stem cells with inducible IDH1R132H for analysis of glioma development and drug testing.
Glioma
Genotype-targeted local therapy of glioma.
Glioma
Glioma Cells in the Tumor Periphery Have a Stem Cell Phenotype.
Glioma
Glioma cells with the IDH1 mutation modulate metabolic fractional flux through pyruvate carboxylase.
Glioma
Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1? and ?-catenin signaling: Possible impact on glioma cell metastasis and chemo-resistance.
Glioma
Glioma grading and IDH1 mutational status: assessment by intravoxel incoherent motion MRI.
Glioma
Glutamate is a non-invasive metabolic biomarker of IDH1 mutant glioma response to temozolomide treatment.
Glioma
High DPP4 expression predicts poor prognosis in patients with low-grade glioma.
Glioma
High S phase kinase-associated protein 2 expression is a potential prognostic biomarker for glioma.
Glioma
High-frequency oscillations in awake patients undergoing brain tumor-related epilepsy surgery.
Glioma
High-throughput immunohistochemical profiling of primary brain tumors and non-neoplastic systemic organs with a specific antibody against the mutant isocitrate dehydrogenase 1 R132H protein.
Glioma
Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring.
Glioma
Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma.
Glioma
Identification and characterization of a novel mutant isocitrate dehydrogenase 1 inhibitor for glioma treatment.
Glioma
Identification of a new selective chemical inhibitor of mutant isocitrate dehydrogenase-1.
Glioma
Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma.
Glioma
Identification of Retinol Binding Protein 1 Promoter Hypermethylation in Isocitrate Dehydrogenase 1 and 2 Mutant Gliomas.
Glioma
Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas.
Glioma
IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Glioma
IDH mutations in cancer and progress toward development of targeted therapeutics.
Glioma
IDH mutations in human glioma.
Glioma
IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas.
Glioma
IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee.
Glioma
IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice.
Glioma
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.
Glioma
IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders.
Glioma
IDH1 and IDH2 mutations in different histologic subtypes and WHO grading gliomas in a sample from Northern Brazil.
Glioma
IDH1 and IDH2 mutations in gliomas.
Glioma
IDH1 and IDH2 mutations in postoperative diffuse glioma-associated epilepsy.
Glioma
IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat.
Glioma
IDH1 mutation diminishes aggressive phenotype in glioma stem cells.
Glioma
IDH1 Mutation in Brain Stem Glioma: Case Report and Review of Literature.
Glioma
IDH1 mutation is associated with seizures and protoplasmic subtype in patients with low-grade gliomas.
Glioma
IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy.
Glioma
IDH1 mutation-associated long non-coding RNA expression profile changes in glioma.
Glioma
IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.
Glioma
IDH1 mutations induce organelle defects via dysregulated phospholipids.
Glioma
IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma.
Glioma
IDH1 R132C mutation is detected in clear cell hepatocellular carcinoma by pyrosequencing.
Glioma
IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.
Glioma
IDH1, lipid metabolism and cancer: Shedding new light on old ideas.
Glioma
IDH1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysis.
Glioma
IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.
Glioma
IDH1-R132H mutation radiosensitizes U87MG glioma cells via epigenetic downregulation of TIGAR.
Glioma
IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas.
Glioma
IDH1/2 mutation detection in gliomas.
Glioma
IDH1R132H in Neural Stem Cells: Differentiation Impaired by Increased Apoptosis.
Glioma
IDH1R132H is intrinsically tumor-suppressive but functionally attenuated by the glutamate-rich cerebral environment.
Glioma
IDH1R¹³²H decreases the proliferation of U87 glioma cells through upregulation of microRNA-128a.
Glioma
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.
Glioma
Illuminating the cross-talk between tumor metabolism and immunity in IDH-mutated cancers.
Glioma
Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas.
Glioma
Imaging Markers of Isocitrate Dehydrogenase-1 Mutations in Gliomas.
Glioma
Immunohistochemical Demonstration of Isocitrate Dehydrogenase 1 (IDH1) Mutation in a Small Subset of Prostatic Carcinomas.
Glioma
In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma.
Glioma
In silico identification of the prognostic biomarkers and therapeutic targets associated with cancer stem cell characteristics of glioma.
Glioma
In vivo characterization of physiological and metabolic changes related to isocitrate dehydrogenase 1 mutation expcression by multiparametric MRI and MRS in a rat model with orthotopically grafted human-derived glioblastoma cell lines.
Glioma
Influence of scalp block on oncological outcomes of high-grade glioma in adult patients with and without isocitrate dehydrogenase-1 mutation.
Glioma
Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice.
Glioma
Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds.
Glioma
Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
Glioma
Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1.
Glioma
Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.
Glioma
Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer.
Glioma
Inhibitor potency varies widely among tumor-relevant human isocitrate dehydrogenase 1 mutants.
Glioma
Interrogation of IDH1 Status in Gliomas by Fourier Transform Infrared Spectroscopy.
Glioma
Intratumoral Susceptibility Signals Reflect Biomarker Status in Gliomas.
Glioma
Intravoxel incoherent motion magnetic resonance imaging in predicting IDH1 gene mutations in high-grade gliomas.
Glioma
Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status.
Glioma
Isocitrate Dehydrogenase 1 Analysis Differentiates Gangliogliomas from Infiltrative Gliomas.
Glioma
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma.
Glioma
Isocitrate dehydrogenase 1 and 2 mutations in gliomas.
Glioma
Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
Glioma
Isocitrate Dehydrogenase 1 Expression in Canine Gliomas.
Glioma
Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
Glioma
Isocitrate dehydrogenase 1 gene variants analysis of glioma patients from Pakistan.
Glioma
Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.
Glioma
Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma.
Glioma
Isocitrate dehydrogenase 1 mutation is associated with reduced levels of inflammation in glioma patients.
Glioma
Isocitrate dehydrogenase 1 mutation subtypes at site 132 and their translational potential in glioma.
Glioma
Isocitrate dehydrogenase 1 R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype.
Glioma
Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
Glioma
Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review.
Glioma
Isocitrate dehydrogenase 1R132H mutation in microglia/macrophages in gliomas: Indication of a significant role of microglia/macrophages in glial tumorigenesis.
Glioma
Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Glioma
Isocitrate dehydrogenase mutations in gliomas.
Glioma
Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.
Glioma
KPNA2 predicts long term survival in patients with anaplastic oligoastrocytomas.
Glioma
Lack of B and T cell reactivity towards IDH1R132H in blood and tumor tissue from LGG patients.
Glioma
LncRNA IDH1-AS1 suppresses cell proliferation and tumor growth in glioma.
Glioma
Local image variance of 7 Tesla SWI is a new technique for preoperative characterization of diffusely infiltrating gliomas: correlation with tumour grade and IDH1 mutational status.
Glioma
Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas.
Glioma
Management of low-grade glioma: a systematic review and meta-analysis.
Glioma
Massive dissemination of adult glioblastomas.
Glioma
Mechanism for enhanced 5-aminolevulinic acid fluorescence in isocitrate dehydrogenase 1 mutant malignant gliomas.
Glioma
Mechanisms underlying the biological changes induced by isocitrate dehydrogenase-1 mutation in glioma cells.
Glioma
Metabolic consequences of oncogenic IDH mutations.
Glioma
Metabolic Landscape of a Genetically Engineered Mouse Model of IDH1 Mutant Glioma.
Glioma
Metabolic Reprogramming in Glioma.
Glioma
Metabolic reprogramming of pyruvate dehydrogenase is essential for the proliferation of glioma cells expressing mutant IDH1.
Glioma
Metabolic syndromes and malignant transformation: where the twain shall meet.
Glioma
Methylation associated genes contribute to the favorable prognosis of gliomas with isocitrate dehydrogenase 1 mutation.
Glioma
Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas.
Glioma
Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system.
Glioma
Molecular classification of gliomas.
Glioma
Molecular Immunohistochemical Profile of Angiocentric Glioma.
Glioma
Molecular markers in low-grade gliomas: predictive or prognostic?
Glioma
Molecular pathogenesis of IDH mutations in gliomas.
Glioma
Molecular profile of tumors with oligodendroglial morphology: Clinical relevance.
Glioma
Morphological and molecular features of astroblastoma, including BRAFV600E mutations, suggest an ontological relationship to other cortical-based gliomas of children and young adults.
Glioma
Moving toward molecular classification of diffuse gliomas in adults.
Glioma
MR Imaging-Based Analysis of Glioblastoma Multiforme: Estimation of IDH1 Mutation Status.
Glioma
MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma.
Glioma
MRI Radiomic Features to Predict IDH1 Mutation Status in Gliomas: A Machine Learning Approach using Gradient Tree Boosting.
Glioma
Multi-institutional noninvasive in vivo characterization of IDH, 1p/19q, and EGFRvIII in glioma using neuro-Cancer Imaging Phenomics Toolkit (neuro-CaPTk).
Glioma
Multi-Label Nonlinear Matrix Completion With Transductive Multi-Task Feature Selection for Joint MGMT and IDH1 Status Prediction of Patient With High-Grade Gliomas.
Glioma
Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.
Glioma
Mutant IDH1 and seizures in patients with glioma.
Glioma
Mutant IDH1 and thrombosis in gliomas.
Glioma
Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Glioma
Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters.
Glioma
Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner.
Glioma
Mutant IDH1 inhibits PI3K/Akt signaling in human glioma.
Glioma
Mutant IDH1 is required for IDH1 mutated tumor cell growth.
Glioma
Mutant IDH1 Promotes Glioma Formation In Vivo.
Glioma
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.
Glioma
Mutant IDH1-Driven Cellular Transformation Increases RAD51-Mediated Homologous Recombination and Temozolomide Resistance.
Glioma
Mutant IDH1: An immunotherapeutic target in tumors.
Glioma
Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence.
Glioma
Mutation of isocitrate dehydrogenase 1 induces glioma cell proliferation via nuclear factor??B activation in a hypoxia?inducible factor 1?? dependent manner.
Glioma
Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.
Glioma
NAD+ depletion radiosensitizes 2-DG-treated glioma cells by abolishing metabolic adaptation.
Glioma
NADP(+)-dependent IDH1(R132) mutation and its relevance for glioma patient survival.
Glioma
New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status.
Glioma
New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M.
Glioma
Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria.
Glioma
Non-invasive in vivo assessment of IDH1 mutational status in glioma.
Glioma
Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma.
Glioma
Noninvasive Prediction of IDH1 Mutation and ATRX Expression Loss in Low-Grade Gliomas Using Multiparametric MR Radiomic Features.
Glioma
Novel canine isocitrate dehydrogenase 1 mutation Y208C attenuates dimerization ability.
Glioma
Novel insights into the pathogenesis of gliomas based on large-scale molecular profiling approaches.
Glioma
Novel Multiplex Bead-Based Assay for Detection of IDH1 and IDH2 Mutations in Myeloid Malignancies.
Glioma
Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas.
Glioma
Oncogenic IDH1 Mutations Promote Enhanced Proline Synthesis through PYCR1 to Support the Maintenance of Mitochondrial Redox Homeostasis.
Glioma
Oncogenic MicroRNA-20a is downregulated by the HIF-1?/c-MYC pathway in IDH1 R132H-mutant glioma.
Glioma
Optical analysis of glioma: Fourier-transform infrared spectroscopy reveals the IDH1 mutation status.
Glioma
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors.
Glioma
Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
Glioma
Papillary tumor of the pineal region: a case involving isocitrate dehydrogenase (IDH) genotyping.
Glioma
Pathological classification of brain tumors.
Glioma
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Glioma
Patterns of Tumor Contrast Enhancement Predict the Prognosis of Anaplastic Gliomas with IDH1 Mutation.
Glioma
PCR-Based Simple Subgrouping Is Validated for Classification of Gliomas and Defines Negative Prognostic Copy Number Aberrations in IDH Mutant Gliomas.
Glioma
Pediatric high-grade astrocytomas: a distinct neuro-oncological paradigm.
Glioma
Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate.
Glioma
PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival.
Glioma
PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas.
Glioma
Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma.
Glioma
Prediction of Overall Survival Based on Isocitrate Dehydrogenase 1 Mutation and 18F-FDG Uptake on PET/CT in Patients With Cerebral Gliomas.
Glioma
Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas.
Glioma
Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma.
Glioma
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
Glioma
Prognostic stratification of gliomatosis cerebri by IDH1(R132H) and INA expression.
Glioma
Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
Glioma
Proteomic analysis of oligodendrogliomas expressing a mutant isocitrate dehydrogenase-1.
Glioma
Qualitative and Quantitative MRI Analysis in IDH1 Genotype Prediction of Lower-Grade Gliomas: A Machine Learning Approach.
Glioma
Quantitative analysis of neurite orientation dispersion and density imaging in grading gliomas and detecting IDH-1 gene mutation status.
Glioma
R132 mutations in canine isocitrate dehydrogenase 1 (IDH1) lead to functional changes.
Glioma
R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/?-catenin signaling.
Glioma
R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1? upregulation in adult glioma.
Glioma
Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs.
Glioma
Radiosensitization and a Less Aggressive Phenotype of Human Malignant Glioma Cells Expressing Isocitrate Dehydrogenase 1 (IDH1) Mutant Protein: Dissecting the Mechanisms.
Glioma
Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing.
Glioma
Rapid and sensitive intraoperative detection of mutations in the isocitrate dehydrogenase 1 and 2 genes during surgery for glioma.
Glioma
Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis.
Glioma
Re-evaluation of nondiagnostic biopsies of suspected low-grade glioma using isocitrate dehydrogenase 1 mutation immunohistochemistry.
Glioma
Re-evaluation of the diagnostic performance of 11C-methionine PET/CT according to the 2016 WHO classification of cerebral gliomas.
Glioma
Relationship between IDH1 mutation and preoperative seizure in low-grade gliomas: A meta-analysis.
Glioma
RELB: A novel prognostic marker for glioblastoma as identified by population-based analysis.
Glioma
Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma.
Glioma
Rosette-forming glioneuronal tumor: a pineal region case with IDH1 and IDH2 mutation analyses and literature review of 43 cases.
Glioma
Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma.
Glioma
Seizures and gliomas - towards a single therapeutic approach.
Glioma
Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas.
Glioma
Sensitive detection of hydroxymethylcytosine levels in normal and neoplastic cells and tissues.
Glioma
Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.
Glioma
Sparse Representation-Based Radiomics for the Diagnosis of Brain Tumors.
Glioma
Survival of diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
Glioma
Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors.
Glioma
Synthesis of [1-13 C-5-12 C]-alpha-ketoglutarate enables noninvasive detection of 2-hydroxyglutarate.
Glioma
Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors.
Glioma
TERT and DNMT1 expression predict sensitivity to decitabine in gliomas.
Glioma
TERT Promoter Mutation Analysis to Distinguish Glioma From Gliosis.
Glioma
Textiloma resembling anaplastic progression of an isocitrate dehydrogenase 1 (IDH1) mutant, low grade glioma.
Glioma
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Glioma
The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.
Glioma
The CpG Island Methylator Phenotype: What's in a Name?
Glioma
The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.
Glioma
The MRI Features and Prognosis of Gliomas Associated With IDH1 Mutation: A Single Center Study in Southwest China.
Glioma
The neural stem-cell marker CD24 is specifically upregulated in IDH-mutant glioma.
Glioma
The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma.
Glioma
The Relationship Between IDH1 Mutation Status and Metabolic Imaging in Nonenhancing Supratentorial Diffuse Gliomas: A 11C-MET PET Study.
Glioma
The Role of CASC2 and miR-21 Interplay in Glioma Malignancy and Patient Outcome.
Glioma
The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells.
Glioma
Tissue mechanics promote IDH1-dependent HIF1?-tenascin C feedback to regulate glioblastoma aggression.
Glioma
Tissue Thiol Concentration in High-Grade Gliomas: Is There any Association Between IDH1 Mutation Presence and Tumoral Cellular Antioxidant Defense?
Glioma
To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma.
Glioma
TROP-2, 5hmC, and IDH1 Expression in Anaplastic Thyroid Carcinoma.
Glioma
Unique Interplay Between Molecular miR-181b/d Biomarkers and Health Related Quality of Life Score in the Predictive Glioma Models.
Glioma
Unraveling the glioma epigenome: from molecular mechanisms to novel biomarkers and therapeutic targets.
Glioma
Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Glioma
Usefulness of immunohistochemical expression analysis of metabolic-related molecules to differentiate between intracranial neoplastic and non-neoplastic lesions.
Glioma
Venous Thromboembolism in Brain Tumors: Risk Factors, Molecular Mechanisms, and Clinical Challenges.
Glioma
Volume-based histogram analysis of dynamic contrast-enhanced MRI for estimation of gliomas IDH1 mutation status.
Glioma
Water Networks and Correlated Motions in Mutant Isocitrate Dehydrogenase 1 (IDH1) Are Critical for Allosteric Inhibitor Binding and Activity.
Glioma
What's New in Grade II and Grade III Gliomas?
Glioma
[Expression of isocitrate dehydrogenase 1 gene R132H and its diagnostic application in glioma].
Glioma
[Relationship between IDH1 mutation and clinic pathologic features in human supratentorial WHO grade II gliomas].
Gliosarcoma
An IDH1-mutated primary gliosarcoma: case report.
Gliosarcoma
Prognostic factors and clinical outcomes in adult primary gliosarcoma patients: a Surveillance, Epidemiology, and End Results (SEER) analysis from 2004 to 2015.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
G6pd Deficiency Does Not Affect the Cytosolic Glutathione or Thioredoxin Antioxidant Defense in Mouse Cochlea.
Glucosephosphate Dehydrogenase Deficiency
G6pd Deficiency Does Not Affect the Cytosolic Glutathione or Thioredoxin Antioxidant Defense in Mouse Cochlea.
Hemangioma
Constitutional abnormalities of IDH1 combined with secondary mutations predispose a patient with Maffucci syndrome to acute lymphoblastic leukemia.
Hemangioma
Maffucci Syndrome with Clival Enchondroma in Nasopharynx: A Case Report.
Hematologic Neoplasms
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.
Hematologic Neoplasms
I-8, a novel inhibitor of mutant IDH1, inhibits cancer progression in vitro and in vivo.
Hematologic Neoplasms
Idh1 mutations contribute to the development of T-cell malignancies in genetically engineered mice.
Hematologic Neoplasms
Illuminating the cross-talk between tumor metabolism and immunity in IDH-mutated cancers.
Hematologic Neoplasms
Mutant Idh2 cooperates with a NUP98-HOXD13 fusion to induce early immature thymocyte precursor ALL.
Hematologic Neoplasms
Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China.
Hematologic Neoplasms
Rapid and reliable detection of IDH1 R132 mutations in acute myeloid leukemia using high-resolution melting curve analysis.
Hematologic Neoplasms
TET2 as an epigenetic master regulator for normal and malignant hematopoiesis.
Hyperaldosteronism
Spironolactone bodies in aldosteronomas and in the attached adrenals. Enzyme histochemical study of 19 cases of primary aldosteronism and a case of aldosteronism due to bilateral diffuse hyperplasia of the zona glomerulosa.
Hyperglycemia
Upregulation of cytosolic NADP(+)-dependent isocitrate dehydrogenase by hyperglycemia protects renal cells against oxidative stress.
Hyperglycemia
Upregulation of cytosolic NADP+-dependent isocitrate dehydrogenase by hyperglycemia protects renal cells against oxidative stress.
Hypokinesia
[Oxidative enzyme activity of the tricarboxylic acid cycle in rat skeletal muscles in hypokinesia]
Hypothyroidism
Changes of activity and kinetics of certain liver and heart enzymes of hypothyroid and T(3)-treated rats.
Infertility, Male
Identification of miRNAs and their targets by high-throughput sequencing and degradome analysis in cytoplasmic male-sterile line NJCMS1A and its maintainer NJCMS1B of soybean.
Infertility, Male
Molecular cloning, sequence characterization of a novel pepper gene NADP-ICDH and its effect on cytoplasmic male sterility.
Intellectual Disability
Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival.
Intellectual Disability
Multicentric Glioma Develops via a Mutant IDH1-Independent Pathway: Immunohistochemical Study of Multicentric Glioma.
isocitrate dehydrogenase (nadp+) deficiency
Mitochondrial NADP+-dependent isocitrate dehydrogenase deficiency increases cisplatin-induced oxidative damage in the kidney tubule cells.
Leukemia
A Model System for Studying the DNMT3A Hotspot Mutation (DNMT3AR882) Demonstrates a Causal Relationship between Its Dominant-Negative Effect and Leukemogenesis.
Leukemia
Association of TP53 Alteration with Tissue Specificity and Patient Outcome of IDH1-Mutant Glioma.
Leukemia
Enzyme activities of NADPH-forming metabolic pathways in normal and leukemic leukocytes.
Leukemia
Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China.
Leukemia
TROP-2, 5hmC, and IDH1 Expression in Anaplastic Thyroid Carcinoma.
Leukemia, Myeloid, Acute
(2R,3S)-Dihydroxybutanoic Acid Synthesis as a Novel Metabolic Function of Mutant Isocitrate Dehydrogenase 1 and 2 in Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation.
Leukemia, Myeloid, Acute
A Zebrafish Model for Evaluating the Function of Human Leukemic Gene IDH1 and Its Mutation.
Leukemia, Myeloid, Acute
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.
Leukemia, Myeloid, Acute
Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.
Leukemia, Myeloid, Acute
Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia.
Leukemia, Myeloid, Acute
Advances in Brain Cancer: Creating Monoallelic Single Point Mutation in IDH1 by Single Base Editing.
Leukemia, Myeloid, Acute
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
Leukemia, Myeloid, Acute
Comparison of high-resolution melting analysis with direct sequencing for the detection of recurrent mutations in DNA methyltransferase 3A and isocitrate dehydrogenase 1 and 2 genes in acute myeloid leukemia patients.
Leukemia, Myeloid, Acute
Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing.
Leukemia, Myeloid, Acute
Diagnostic testing for IDH1 and IDH2 variants in acute myeloid leukemia an algorithmic approach using high-resolution melting curve analysis.
Leukemia, Myeloid, Acute
Differential activity of NADPH-producing dehydrogenases renders rodents unsuitable models to study IDH1R132 mutation effects in human glioblastoma.
Leukemia, Myeloid, Acute
Discovery and Optimization of 2H-1?2-Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer.
Leukemia, Myeloid, Acute
Discovery and Optimization of Allosteric Inhibitors of Mutant Isocitrate Dehydrogenase 1 (R132H IDH1) Displaying Activity in Human Acute Myeloid Leukemia Cells.
Leukemia, Myeloid, Acute
Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.
Leukemia, Myeloid, Acute
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
Leukemia, Myeloid, Acute
Enzyme activities of NADPH-forming metabolic pathways in normal and leukemic leukocytes.
Leukemia, Myeloid, Acute
Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
Leukemia, Myeloid, Acute
FDA Approval Summary: Ivosidenib for relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-1 mutation.
Leukemia, Myeloid, Acute
Functions of idh1 and its mutation in the regulation of developmental hematopoiesis in zebrafish.
Leukemia, Myeloid, Acute
IDH mutations in cancer and progress toward development of targeted therapeutics.
Leukemia, Myeloid, Acute
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Leukemia, Myeloid, Acute
IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders.
Leukemia, Myeloid, Acute
IDH1 and IDH2 mutations in pediatric acute leukemia.
Leukemia, Myeloid, Acute
IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma.
Leukemia, Myeloid, Acute
IDH1 R132C mutation is detected in clear cell hepatocellular carcinoma by pyrosequencing.
Leukemia, Myeloid, Acute
IDH1, lipid metabolism and cancer: Shedding new light on old ideas.
Leukemia, Myeloid, Acute
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.
Leukemia, Myeloid, Acute
IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen.
Leukemia, Myeloid, Acute
Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1.
Leukemia, Myeloid, Acute
Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations.
Leukemia, Myeloid, Acute
Inhibitor potency varies widely among tumor-relevant human isocitrate dehydrogenase 1 mutants.
Leukemia, Myeloid, Acute
Inhibitory effects of voriconazole, itraconazole and fluconazole on the pharmacokinetic profiles of ivosidenib in rats by UHPLC-MS/MS.
Leukemia, Myeloid, Acute
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia.
Leukemia, Myeloid, Acute
Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Ivosidenib induction therapy complicated by myopericarditis and cardiogenic shock: A case report and literature review.
Leukemia, Myeloid, Acute
Metabolic consequences of oncogenic IDH mutations.
Leukemia, Myeloid, Acute
Metabolic syndromes and malignant transformation: where the twain shall meet.
Leukemia, Myeloid, Acute
Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Leukemia, Myeloid, Acute
Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer.
Leukemia, Myeloid, Acute
Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2.
Leukemia, Myeloid, Acute
Mutant IDH1 is required for IDH1 mutated tumor cell growth.
Leukemia, Myeloid, Acute
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.
Leukemia, Myeloid, Acute
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.
Leukemia, Myeloid, Acute
Novel canine isocitrate dehydrogenase 1 mutation Y208C attenuates dimerization ability.
Leukemia, Myeloid, Acute
Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Oncometabolite d-2-hydroxyglutarate impairs ?-ketoglutarate dehydrogenase and contractile function in rodent heart.
Leukemia, Myeloid, Acute
Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.
Leukemia, Myeloid, Acute
PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction.
Leukemia, Myeloid, Acute
Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies.
Leukemia, Myeloid, Acute
Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.
Leukemia, Myeloid, Acute
Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas.
Leukemia, Myeloid, Acute
Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China.
Leukemia, Myeloid, Acute
Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis.
Leukemia, Myeloid, Acute
Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance.
Leukemia, Myeloid, Acute
Rapid and reliable detection of IDH1 R132 mutations in acute myeloid leukemia using high-resolution melting curve analysis.
Leukemia, Myeloid, Acute
Some novel features of IDH1-mutated acute myeloid leukemia revealed in Chinese patients.
Leukemia, Myeloid, Acute
Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors.
Leukemia, Myeloid, Acute
The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.
Leukemia, Myeloid, Acute
The oncometabolite R-2-hydroxyglutarate activates NF-?B-dependent tumor-promoting stromal niche for acute myeloid leukemia cells.
Leukemia, Myeloid, Acute
The Synonymous Isocitrate Dehydrogenase 1 315C>T SNP Confers an Adverse Prognosis in Egyptian Adult Patients with NPM1-/CEBPA-Negative Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia.
Leukemia, Myeloid, Acute
Water Networks and Correlated Motions in Mutant Isocitrate Dehydrogenase 1 (IDH1) Are Critical for Allosteric Inhibitor Binding and Activity.
Leukemia, Myeloid, Acute
[Clinical significance of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].
Leukemia, Myeloid, Acute
[Detection of isocitrate dehydrogenase 1 gene mutation in 205 AML patients and its clinical significance].
Leukemia, T-Cell
Mutant Idh2 cooperates with a NUP98-HOXD13 fusion to induce early immature thymocyte precursor ALL.
Liver Neoplasms
Mutant IDH inhibits HNF-4? to block hepatocyte differentiation and promote biliary cancer.
Lung Neoplasms
Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis.
Lung Neoplasms
Isocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancer.
Lung Neoplasms
Non-small cell lung cancers with isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations.
Lymphoma
Analysis of ALK, IDH1, IDH2 and MMP8 somatic mutations in differentiated thyroid cancers.
Lymphoma
Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China.
Lymphoma
Sparse Representation-Based Radiomics for the Diagnosis of Brain Tumors.
Lymphoma, B-Cell
How I treat acute myeloid leukemia in the era of new drugs.
Lymphoma, T-Cell
The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.
Malaria
NADP-specific isocitrate dehydrogenase from the simian malaria parasite Plasmodium knowlesi: partial purification and characterization.
Melanoma
Advances in Brain Cancer: Creating Monoallelic Single Point Mutation in IDH1 by Single Base Editing.
Melanoma
Isocitrate dehydrogenase 1 mutations in melanoma frequently co-occur with NRAS mutations.
Melanoma
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.
Metabolic Diseases
Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate.
Myelodysplastic Syndromes
Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing.
Myelodysplastic Syndromes
IDH mutations in cancer and progress toward development of targeted therapeutics.
Myelodysplastic Syndromes
Myelodysplastic Syndrome and Sweet's Syndrome Are Associated with a Mutation in Isocitrate Dehydrogenase 1.
Myelodysplastic Syndromes
[Relationship between clinical characteristics and myelodysplastic syndrome patients with isocitrate dehydrogenase gene mutations].
Myocardial Infarction
[The dose-dependent influence of 3,5-dicarbometoxyphenylbiguanide on activity of the glutathione antioxidant system in heart and blood serum of rats with the experimental myocardial infarction].
Neoplasm Metastasis
Extracranial Metastasis of IDH-1 Wild Type Glioblastomas.
Neoplasm Metastasis
SIRT2-dependent IDH1 deacetylation inhibits colorectal cancer and liver metastases.
Neoplasm Metastasis
Skeletal spread of an anaplastic astrocytoma (WHO grade III) and preservation of histopathological properties within metastases.
Neoplasms
A case of multicentric gliomas in both supra- and infratentorial regions with different histology: a case report.
Neoplasms
A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas.
Neoplasms
A juvenile case of epilepsy-associated, isocitrate dehydrogenase wild-type/histone 3 wild-type diffuse glioma with a rare BRAF A598T mutation.
Neoplasms
A map of the altered glioma metabolism.
Neoplasms
A novel high-sensitivity assay to detect a small fraction of mutant IDH1 using droplet digital PCR.
Neoplasms
A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation.
Neoplasms
A PRDX1-p38? heterodimer amplifies MET-driven invasion of IDH-wildtype and IDH-mutant gliomas.
Neoplasms
A strategy for poisoning cancer cell metabolism: Inhibition of oxidative phosphorylation coupled to anaplerotic saturation.
Neoplasms
Action at a distance: allostery and the development of drugs to target cancer cell metabolism.
Neoplasms
ADHFE1 is a MYC-linked oncogene that induces metabolic reprogramming and cellular de-differentiation in breast cancer.
Neoplasms
Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951.
Neoplasms
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
Neoplasms
Analysis of ALK, IDH1, IDH2 and MMP8 somatic mutations in differentiated thyroid cancers.
Neoplasms
Analysis of cerebrospinal fluid metabolites in patients with primary or metastatic central nervous system tumors.
Neoplasms
Analysis of Mutant Isocitrate Dehydrogenase 1 Immunoexpression, Ki-67 and Programmed Death Ligand 1 in Diffuse Astrocytic Tumours : Study of Single Center in Bandung, Indonesia.
Neoplasms
Anaplastic astrocytoma cells not detectable on autopsy following long-term temozolomide treatment: A case report.
Neoplasms
Anaplastic astrocytomas with abundant Rosenthal fibers in elderly patients: A diagnostic pitfall of high-grade gliomas.
Neoplasms
Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas.
Neoplasms
Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays.
Neoplasms
Association of TP53 Alteration with Tissue Specificity and Patient Outcome of IDH1-Mutant Glioma.
Neoplasms
Awake craniotomies for epileptic gliomas: intraoperative and postoperative seizure control and prognostic factors.
Neoplasms
BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1.
Neoplasms
Biliary cancer: Utility of next-generation sequencing for clinical management.
Neoplasms
Biochemical, Cellular and Biophysical Characterization of a Potent Inhibitor of Mutant Isocitrate Dehydrogenase IDH1.
Neoplasms
Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastoma.
Neoplasms
Biological Role and Therapeutic Potential of IDH Mutations in Cancer.
Neoplasms
Brain T1? mapping for grading and IDH1 gene mutation detection of gliomas: a preliminary study.
Neoplasms
Cancer metabolism: Key players in metabolic reprogramming.
Neoplasms
Cancer-associated IDH mutations induce Glut1 expression and glucose metabolic disorders through a PI3K/Akt/mTORC1-Hif1? axis.
Neoplasms
Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia.
Neoplasms
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
Neoplasms
Changes in enzyme pattern of Ehrlich ascites tumor cells following serial cultivation in media with increased (hypertonic) NaCl content.
Neoplasms
Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms.
Neoplasms
Chondroma arising from the spinal dura mater at the thoracic level: A case report with molecular analysis.
Neoplasms
Clinicopathological Analysis of HIF-1alpha and TERT on Survival Outcome in Glioblastoma Patients: A Prospective, Single Institution Study.
Neoplasms
Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors.
Neoplasms
Combined ATRX/IDH1 immunohistochemistry predicts genotype of oligoastrocytomas.
Neoplasms
Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.
Neoplasms
Comparative analysis of the diffusion kurtosis imaging and diffusion tensor imaging in grading gliomas, predicting tumour cell proliferation and IDH-1 gene mutation status.
Neoplasms
Concurrent IDH1 and SMARCB1 Mutations in Pediatric Medulloblastoma: A Case Report.
Neoplasms
Congenital glioneuronal tumor with neuropil-like islands.
Neoplasms
Congenital oligodendroglioma: clinicopathologic and molecular assessment with review of the literature.
Neoplasms
Consumption of NADPH for 2-HG Synthesis Increases Pentose Phosphate Pathway Flux and Sensitizes Cells to Oxidative Stress.
Neoplasms
Correlation between IDH, ATRX, and TERT promoter mutations in glioma.
Neoplasms
Correlation of immunohistochemical expression of HIF-1alpha and IDH1 with clinicopathological and therapeutic data of moroccan glioblastoma and survival analysis.
Neoplasms
Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
Neoplasms
Cystathionine-?-lyase drives antioxidant defense in cysteine-restricted IDH1-mutant astrocytomas.
Neoplasms
D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice.
Neoplasms
Detection of Metabolic Changes Induced via Drug Treatments in Live Cancer Cells and Tissue Using Raman Imaging Microscopy.
Neoplasms
Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
Neoplasms
Development of a Rapid and Sensitive IDH1/2 Mutation Detection Method for Glial Tumors and a Comparative Mutation Analysis of 236 Glial Tumor Samples.
Neoplasms
Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone.
Neoplasms
Differential activity of NADPH-producing dehydrogenases renders rodents unsuitable models to study IDH1R132 mutation effects in human glioblastoma.
Neoplasms
Diffusion kurtosis imaging combined with molecular markers as a comprehensive approach to predict overall survival in patients with gliomas.
Neoplasms
Discovery and Optimization of 2H-1?2-Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer.
Neoplasms
Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors.
Neoplasms
Discovery of ?-mangostin as a novel competitive inhibitor against mutant isocitrate dehydrogenase-1.
Neoplasms
Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1).
Neoplasms
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.
Neoplasms
Distinct demographic profile and molecular markers of primary CNS tumor in 1873 adolescent and young adult patient population.
Neoplasms
Docosahexaenoic Acid Modulates the Enterocyte Caco-2 Cell Expression of MicroRNAs Involved in Lipid Metabolism.
Neoplasms
Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.
Neoplasms
Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.
Neoplasms
Energy Metabolism in IDH1 Wild-Type and IDH1-Mutated Glioblastoma Stem Cells: A Novel Target for Therapy?
Neoplasms
Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate.
Neoplasms
Epithelioid glioblastoma presenting as multicentric glioma: A case report and review of the literature.
Neoplasms
Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
Neoplasms
Exosomal IDH1 increases the resistance of colorectal cancer cells to 5-Fluorouracil.
Neoplasms
Exploring the Allosteric Territory of Protein Function.
Neoplasms
Extracranial growth of glioblastoma multiforme.
Neoplasms
Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review.
Neoplasms
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
Neoplasms
From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma.
Neoplasms
Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms.
Neoplasms
Functional requirement of a wild-type allele for mutant IDH1 to suppress anchorage-independent growth through redox homeostasis.
Neoplasms
Generation of induced neural stem cells with inducible IDH1R132H for analysis of glioma development and drug testing.
Neoplasms
Genetic alterations and signaling pathways in the evolution of gliomas.
Neoplasms
Genetic and Clinical Characterization of HOXB2 in Glioma.
Neoplasms
Genetic and epigenetic alterations in primary-progressive paired oligodendroglial tumors.
Neoplasms
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
Neoplasms
Genetic Factors Affecting Intraoperative 5-aminolevulinic Acid-induced Fluorescence of Diffuse Gliomas.
Neoplasms
Genome-wide transcriptional analyses of Chinese patients reveal cell migration is attenuated in IDH1-mutant glioblastomas.
Neoplasms
Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.
Neoplasms
Gliomatosis cerebri: no evidence for a separate brain tumor entity.
Neoplasms
Gliosarcoma arising from oligodendroglioma (Oligosarcoma): A case report with genetic analyses.
Neoplasms
GSH and GABA decreases in IDH1-mutated low-grade gliomas detected by HERMES spectral editing at 3 T in vivo.
Neoplasms
Heterozygous IDH1R132H/WT created by "single base editing" inhibits human astroglial cell growth by downregulating YAP.
Neoplasms
High expression of cystine-glutamate antiporter xCT (SLC7A11) is an independent biomarker for epileptic seizures at diagnosis in glioma.
Neoplasms
High frequency of H3K27M immunopositivity in adult thalamic glioblastoma.
Neoplasms
High-frequency oscillations in awake patients undergoing brain tumor-related epilepsy surgery.
Neoplasms
Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Neoplasms
Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring.
Neoplasms
Hypoxia Induces Production of L-2-Hydroxyglutarate.
Neoplasms
I-8, a novel inhibitor of mutant IDH1, inhibits cancer progression in vitro and in vivo.
Neoplasms
Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer.
Neoplasms
Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer.
Neoplasms
Identification of Circulating Genomic and Metabolic Biomarkers in Intrahepatic Cholangiocarcinoma.
Neoplasms
Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis.
Neoplasms
Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images.
Neoplasms
IDH mutations in cancer and progress toward development of targeted therapeutics.
Neoplasms
IDH mutations in liver cell plasticity and biliary cancer.
Neoplasms
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.
Neoplasms
IDH1 and IDH2 mutations in gliomas.
Neoplasms
IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy.
Neoplasms
IDH1 mutation of gliomas with long-term survival analysis.
Neoplasms
IDH1 Mutation Promotes Tumorigenesis by Inhibiting JNK Activation and Apoptosis Induced by Serum Starvation.
Neoplasms
IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism.
Neoplasms
IDH1 Mutations in Oligodendroglial Tumors: Comparative Analysis of Direct Sequencing, Pyrosequencing, Immunohistochemistry, Nested PCR and PNA-Mediated Clamping PCR.
Neoplasms
IDH1 mutations induce organelle defects via dysregulated phospholipids.
Neoplasms
IDH1, lipid metabolism and cancer: Shedding new light on old ideas.
Neoplasms
IDH1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysis.
Neoplasms
IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.
Neoplasms
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.
Neoplasms
Illuminating the cross-talk between tumor metabolism and immunity in IDH-mutated cancers.
Neoplasms
Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas.
Neoplasms
Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
Neoplasms
Immunohistochemical characterisation and histopathology of astrocytic neoplasms at a tertiary Nigerian hospital.
Neoplasms
Immunohistochemical Demonstration of Isocitrate Dehydrogenase 1 (IDH1) Mutation in a Small Subset of Prostatic Carcinomas.
Neoplasms
Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds.
Neoplasms
Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
Neoplasms
Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.
Neoplasms
Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer.
Neoplasms
Intracellular cholesterol biosynthesis in enchondroma and chondrosarcoma.
Neoplasms
Intraoperative perception and estimates on extent of resection during awake glioma surgery: overcoming the learning curve.
Neoplasms
Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT).
Neoplasms
Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.
Neoplasms
Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
Neoplasms
Isocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancer.
Neoplasms
Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate.
Neoplasms
Isocitrate dehydrogenase 2 inhibits gastric cancer cell invasion via matrix metalloproteinase 7.
Neoplasms
Isocitrate Dehydrogenase 2 Suppresses the Invasion of Hepatocellular Carcinoma Cells via Matrix Metalloproteinase 9.
Neoplasms
Isocitrate dehydrogenase variants in cancer - Cellular consequences and therapeutic opportunities.
Neoplasms
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Neoplasms
Ivosidenib: First Global Approval.
Neoplasms
Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate.
Neoplasms
Lactate dehydrogenase A silencing in IDH mutant gliomas.
Neoplasms
Local image variance of 7 Tesla SWI is a new technique for preoperative characterization of diffusely infiltrating gliomas: correlation with tumour grade and IDH1 mutational status.
Neoplasms
Long-term tumor control of spinal dissemination of cerebellar glioblastoma multiforme by combined adjuvant bevacizumab antibody therapy: a case report.
Neoplasms
Maffucci syndrome and neoplasms: a case report and review of the literature.
Neoplasms
Magnetic resonance spectroscopy for the study of cns malignancies.
Neoplasms
Malignant glioma: lessons from genomics, mouse models, and stem cells.
Neoplasms
Malignant Transformation of a Rosette-Forming Glioneuronal Tumor with IDH1 Mutation: A Case Report and Literature Review.
Neoplasms
Metabolic consequences of oncogenic IDH mutations.
Neoplasms
Metabolic Reprogramming in Glioma.
Neoplasms
Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism.
Neoplasms
Molecular Aberrations Associated with Seizure Control in Diffuse Astrocytic and Oligodendroglial Tumors.
Neoplasms
Molecular classification of gliomas.
Neoplasms
Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1/2 mutations.
Neoplasms
Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency.
Neoplasms
Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network.
Neoplasms
MR-guided focused ultrasound liquid biopsy enriches circulating biomarkers in patients with brain tumors.
Neoplasms
MRI features predict survival and molecular markers in diffuse lower-grade gliomas.
Neoplasms
Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer.
Neoplasms
Mutant IDH and non-mutant chondrosarcomas display distinct cellular metabolomes.
Neoplasms
Mutant IDH1 and seizures in patients with glioma.
Neoplasms
Mutant IDH1 is required for IDH1 mutated tumor cell growth.
Neoplasms
Mutant IDH1: An immunotherapeutic target in tumors.
Neoplasms
Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence.
Neoplasms
Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism.
Neoplasms
NAD Synthesis Pathway Interference is a Viable Therapeutic Strategy for Chondrosarcoma.
Neoplasms
Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection.
Neoplasms
New Chondrosarcoma Cell Lines with Preserved Stem Cell Properties to Study the Genomic Drift During In Vitro/In Vivo Growth.
Neoplasms
New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.
Neoplasms
New-Onset Postoperative Seizures in Patients With Diffuse Gliomas: A Risk Assessment Analysis.
Neoplasms
Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria.
Neoplasms
Novel Multiplex Bead-Based Assay for Detection of IDH1 and IDH2 Mutations in Myeloid Malignancies.
Neoplasms
Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2.
Neoplasms
Oncogenic IDH1 Mutations Promote Enhanced Proline Synthesis through PYCR1 to Support the Maintenance of Mitochondrial Redox Homeostasis.
Neoplasms
Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype.
Neoplasms
Oncometabolites suppress DNA repair by disrupting local chromatin signalling.
Neoplasms
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors.
Neoplasms
Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come.
Neoplasms
Overexpression of the phospholipase A2 group V gene in glioma tumors is associated with poor patient prognosis.
Neoplasms
Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.
Neoplasms
Paradoxical prognostic impact of TERT promoter mutations in gliomas depends on different histological and genetic backgrounds.
Neoplasms
Pathologic diversity of glioneuronal tumor with neuropil-like islands: A histological and immunohistochemical study with a special reference to isocitrate dehydrogenase 1 (IDH1) in 5 cases.
Neoplasms
Pathological classification of brain tumors.
Neoplasms
PDGFRA Amplification is Common in Pediatric and Adult High-Grade Astrocytomas and Identifies a Poor Prognostic Group in IDH1 Mutant Glioblastoma.
Neoplasms
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors.
Neoplasms
Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma.
Neoplasms
Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas.
Neoplasms
Pilocytic Astrocytoma with Adipocytic Differentiation: A Rare Histological Variation.
Neoplasms
Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.
Neoplasms
Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
Neoplasms
Preoperative neutrophil-lymphocyte ratio correlated with glioma grading and glioblastoma survival.
Neoplasms
Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss.
Neoplasms
Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma.
Neoplasms
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
Neoplasms
Promoter methylation of WNT inhibitory factor-1 and expression pattern of WNT/?-catenin pathway in human astrocytoma: pathologic and prognostic correlations.
Neoplasms
Quantitative analysis of neurite orientation dispersion and density imaging in grading gliomas and detecting IDH-1 gene mutation status.
Neoplasms
R132H Mutation in IDH1 Gene is Associated with Increased Tumor HIF1-Alpha and Serum VEGF Levels in Primary Glioblastoma Multiforme.
Neoplasms
Radiomics may increase the prognostic value for survival in glioblastoma patients when combined with conventional clinical and genetic prognostic models.
Neoplasms
Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.
Neoplasms
Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma.
Neoplasms
Rhabdoid glioblastoma is distinguishable from classical glioblastoma by cytogenetics and molecular genetics.
Neoplasms
Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients.
Neoplasms
RNA-Binding Protein HuR Regulates Both Mutant and Wild-Type IDH1 in IDH1-Mutated Cancer.
Neoplasms
Sarcoma-like tumor originating from oligodendroglioma.
Neoplasms
Serum-free culture success of glial tumors is related to specific molecular profiles and expression of extracellular matrix-associated gene modules.
Neoplasms
SIRT2-dependent IDH1 deacetylation inhibits colorectal cancer and liver metastases.
Neoplasms
Skeletal spread of an anaplastic astrocytoma (WHO grade III) and preservation of histopathological properties within metastases.
Neoplasms
Small interfering RNA-mediated silencing of mitochondrial NADP+-dependent isocitrate dehydrogenase enhances the sensitivity of HeLa cells toward tumor necrosis factor-alpha and anticancer drugs.
Neoplasms
Sterol Regulatory Element Binding Protein Regulates the Expression and Metabolic Functions of Wild-Type and Oncogenic IDH1.
Neoplasms
Structural basis for multi-specific peptide recognition by the anti-IDH1/2 monoclonal antibody, MsMab-1.
Neoplasms
Survival of diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
Neoplasms
Synthesis of [1-13 C-5-12 C]-alpha-ketoglutarate enables noninvasive detection of 2-hydroxyglutarate.
Neoplasms
Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors.
Neoplasms
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Neoplasms
The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival.
Neoplasms
The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes.
Neoplasms
The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.
Neoplasms
The effect of race on the prognosis of the glioblastoma patient: a brief review.
Neoplasms
The Evaluation of AREG, MMP-2, CHI3L1, GFAP, and OPN Serum Combined Value in Astrocytic Glioma Patients' Diagnosis and Prognosis.
Neoplasms
The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation.
Neoplasms
The Pluripotent Stem-Cell Marker Alkaline Phosphatase is Highly Expressed in Refractory Glioblastoma with DNA Hypomethylation.
Neoplasms
The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.
Neoplasms
The Role of CASC2 and miR-21 Interplay in Glioma Malignancy and Patient Outcome.
Neoplasms
The Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells.
Neoplasms
The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells.
Neoplasms
TOF-SIMS analysis of an isocitrate dehydrogenase 1 mutation-associated oncometabolite in cancer cells.
Neoplasms
Transcortical insular glioma resection: clinical outcome and predictors.
Neoplasms
Tumor location and IDH1 mutation may predict intraoperative seizures during awake craniotomy.
Neoplasms
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Neoplasms
Unique Interplay Between Molecular miR-181b/d Biomarkers and Health Related Quality of Life Score in the Predictive Glioma Models.
Neoplasms
Upregulation of Long Noncoding RNA Small Nucleolar RNA Host Gene 18 Promotes Radioresistance of Glioma by Repressing Semaphorin 5A.
Neoplasms
Virtual mutagenesis of isocitrate dehydrogenase 1 involved in glioblastoma multiforme.
Neoplasms
Virtual screening of potential anticancer drugs based on microbial products.
Neoplasms
Water Networks and Correlated Motions in Mutant Isocitrate Dehydrogenase 1 (IDH1) Are Critical for Allosteric Inhibitor Binding and Activity.
Neoplasms
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.
Neoplasms
What's New in Grade II and Grade III Gliomas?
Neoplasms
Wild-type IDH2 promotes the Warburg effect and tumor growth through HIF1? in lung cancer.
Neoplasms
Wild-Type Isocitrate Dehydrogenase 1 Over-Expression is Related to Cancer Stem Cells Survival in Lung Adenocarcinoma.
Neoplasms
Withaferin A suppresses tumor promoter 12-O-tetradecanoylphorbol 13-acetate-induced decreases in isocitrate dehydrogenase 1 activity and mitochondrial function in skin epidermal JB6 cells.
Neoplasms
[Classification of gliomas. Current progress and perspectives].
Neoplasms
[Clinical, immunohistochemical, and molecular genetic prognostic factors in adult patients with glioblastoma].
Neoplasms
[Expression and catalytic properties NADP-isocitrate dehydrogenase from the rat liver under normal conditions and following administration of tumor necrosis factor-alpha or thioctic acid].
Neoplasms
[Feature analysis of IDH1 mutation in oligodendroglial tumors].
Neoplasms
[Isozymes of NADP-dependent isocitrate dehydrogenase in normal and tumor tissues of various mouse strains and their hybrids]
Neoplasms
[Value of Serum Tumor Marker Isocitrate Dehydrogenase 1 in the Diagnosis of Lung Cancer].
Neoplasms, Neuroepithelial
Diffuse leptomeningeal neuroepithelial tumor: 9 pediatric cases with chromosome 1p/19q deletion status and IDH1 (R132H) immunohistochemistry.
Neuroblastoma
Minimally-Myelosuppressive Asparaginase-Containing Induction Regimen for Treatment of a Jehovah's Witness with mutant IDH1/NPM1/NRAS Acute Myeloid Leukemia.
Neurocytoma
A case of oligodendroglioma with prominent neuronal differentiation.
Neuroectodermal Tumors, Primitive
Massive dissemination of adult glioblastomas.
Neurofibromatoses
Glioblastoma in a female neurofibromatosis 1 patient without IDH1, BRAF V600E, and TERT promoter mutations: A case report.
Neurofibromatosis 1
Glioblastoma in a female neurofibromatosis 1 patient without IDH1, BRAF V600E, and TERT promoter mutations: A case report.
Oligodendroglioma
A case of oligodendroglioma with prominent neuronal differentiation.
Oligodendroglioma
Anaplastic Oligodendroglioma: Advances and Treatment Options.
Oligodendroglioma
Arteriovenous malformation within an isocitrate dehydrogenase 1 mutated anaplastic oligodendroglioma.
Oligodendroglioma
Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing.
Oligodendroglioma
Diffuse leptomeningeal neuroepithelial tumor: 9 pediatric cases with chromosome 1p/19q deletion status and IDH1 (R132H) immunohistochemistry.
Oligodendroglioma
Findings from positron emission tomography and genetic analyses for cerebellar liponeurocytoma.
Oligodendroglioma
Generation and Performance of R132H Mutant IDH1 Rabbit Monoclonal Antibody.
Oligodendroglioma
Genetic alterations and signaling pathways in the evolution of gliomas.
Oligodendroglioma
Gliosis versus glioma?: don't grade until you know.
Oligodendroglioma
IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients.
Oligodendroglioma
Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation.
Oligodendroglioma
Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
Oligodendroglioma
Metabolic modulation of epigenetics in gliomas.
Oligodendroglioma
Molecular pathogenesis of IDH mutations in gliomas.
Oligodendroglioma
Molecular profile of oligodendrogliomas in young patients.
Oligodendroglioma
Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
Oligodendroglioma
No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas.
Oligodendroglioma
PCR- and Restriction Endonuclease-Based Detection of IDH1 Mutations.
Oligodendroglioma
Proteomic analysis of oligodendrogliomas expressing a mutant isocitrate dehydrogenase-1.
Oligodendroglioma
Recurrent Glioma With Lineage Conversion From Oligodendroglioma to Astrocytoma in Two Cases.
Oligodendroglioma
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Osteosarcoma
The expression and significance of IDH1 and p53 in osteosarcoma.
Osteosarcoma
Up-regulated isocitrate dehydrogenase 1 suppresses proliferation, migration and invasion in osteosarcoma: In vitro and in vivo.
Polycythemia Vera
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
IDH1 and IDH2 mutations in pediatric acute leukemia.
Primary Myelofibrosis
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.
Reperfusion Injury
Role of cytosolic NADP+-dependent isocitrate dehydrogenase in ischemia-reperfusion injury in mouse kidney.
Retinitis Pigmentosa
Insights from retinitis pigmentosa into the roles of isocitrate dehydrogenases in the Krebs cycle.
Retinoblastoma
An R132H Mutation in Isocitrate Dehydrogenase 1 Enhances p21 Expression and Inhibits Phosphorylation of Retinoblastoma Protein in Glioma Cells.
Sarcoma
Glioblastoma in a female neurofibromatosis 1 patient without IDH1, BRAF V600E, and TERT promoter mutations: A case report.
Sarcoma
Glioblastoma in neurofibromatosis 1 patients without IDH1, BRAF V600E, and TERT promoter mutations.
Sarcoma
Molecular classification of gliomas.
Sarcoma
Sheep gene mapping: additional DNA markers included (CASB, CASK, LALBA, IGF-1 and AMH).
Sarcoma
[Classification of gliomas. Current progress and perspectives].
Seizures
Aberrant neuronal differentiation is common in glioma but is associated neither with epileptic seizures nor with better survival.
Seizures
Awake craniotomies for epileptic gliomas: intraoperative and postoperative seizure control and prognostic factors.
Seizures
High-frequency oscillations in awake patients undergoing brain tumor-related epilepsy surgery.
Seizures
IDH1 and IDH2 mutations in postoperative diffuse glioma-associated epilepsy.
Seizures
Molecular Aberrations Associated with Seizure Control in Diffuse Astrocytic and Oligodendroglial Tumors.
Seizures
Mutant IDH1 and seizures in patients with glioma.
Seizures
New-Onset Postoperative Seizures in Patients With Diffuse Gliomas: A Risk Assessment Analysis.
Seizures
Prognostic Factors and Survival of Gliomatosis Cerebri: A Systematic Review and Meta-Analysis.
Seizures
Relationship between IDH1 mutation and preoperative seizure in low-grade gliomas: A meta-analysis.
Seizures
Tumor location and IDH1 mutation may predict intraoperative seizures during awake craniotomy.
Starvation
Cloning and expression analysis of the cytosolic NADP(+)-dependent isocitrate dehydrogenase from potato. Implications for nitrogen metabolism.
Starvation
IDH1 Mutation Promotes Tumorigenesis by Inhibiting JNK Activation and Apoptosis Induced by Serum Starvation.
Starvation
Purification, properties and enhanced expression under nitrogen starvation of the NADP+-isocitrate dehydrogenase from the cyanobacterium Phormidium laminosum.
Starvation
The NADP+-isocitrate dehydrogenase gene (icd) is nitrogen regulated in cyanobacteria.
Sweet Syndrome
Histiocytoid Sweet syndrome harboring an isocitrate dehydrogenase 1 mutation: A case report and retrospective analysis of 29 cases of histiocytoid Sweet syndrome.
Sweet Syndrome
Myelodysplastic Syndrome and Sweet's Syndrome Are Associated with a Mutation in Isocitrate Dehydrogenase 1.
Thrombocythemia, Essential
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.
Thyroid Neoplasms
Analysis of ALK, IDH1, IDH2 and MMP8 somatic mutations in differentiated thyroid cancers.
Thyroid Neoplasms
Differential activity of NADPH-producing dehydrogenases renders rodents unsuitable models to study IDH1R132 mutation effects in human glioblastoma.
Thyroid Neoplasms
Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer.
Thyroid Neoplasms
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.
Tuberculosis
Determination of Phosphorylation Sites for NADP-specific Isocitrate Dehydrogenase from Mycobacterium tuberculosis.
Tuberculosis
Structural, Kinetic and Chemical Mechanism of Isocitrate Dehydrogenase-1 from Mycobacterium tuberculosis.
Venous Thromboembolism
Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism.
Vitamin E Deficiency
Cellular membranes and membrane-bound enzymes in vitamin E deficiency. A histochemical, cytochemical, biochemical, and morphologic study of the liver of the Pekin duckling.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1.1.1.42 isocitrate dehydrogenase (NADP+)
more
top
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). 
